PRM Proteome Sciences plc
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM); SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. Proteome Sciences plc was incorporated in 1993 and is based in Cobham, the United Kingdom.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Proteome Sciences (LON: PRM)
›
Proteome Sciences (LON: PRM) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 32 employees.
The shares were at 0.9700 GBp on 20 November 2026, down 37.4% over 52 weeks. Its 52-week range is 1.000 GBp to 4.400 GBp, and it trades at the bottom of that range.
Its market capitalisation is 3.40M GBP.
Proteome Sciences reports return on equity of 32.1%, an operating margin of -60.6% and revenue up 0.8% year over year.
Its debt exceeds its cash by 14.85M GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.